WGU D116 ADVANCED PHARMACOLOGY FINAL EXAM
OBJECTIVE ASSESSMENT QUESTIONS AND ANSWERS |
LATEST UPDATE
CORE DOMAINS
• Pharmacokinetics & Pharmacodynamics
• Cardiovascular & Renal Pharmacology
• Respiratory & Allergy Pharmacology
• Endocrine & Metabolic Pharmacology
• Neurologic & Psychiatric Pharmacology
• Infectious Disease & Antimicrobials
• Special Populations, Toxicology & Clinical Application
INTRODUCTION
This comprehensive assessment evaluates the candidate's mastery of
advanced pharmacology principles required for safe, evidence-based
prescribing at the APRN level. It measures competency across
pharmacokinetics, pharmacodynamics, drug classifications, adverse
effects, drug interactions, and therapeutic monitoring. The examination
employs multiple-choice and scenario-based questions that test clinical
reasoning, prioritization, and application of pharmacologic principles to
complex patient scenarios. Candidates must demonstrate the ability to
evaluate drug therapy, recognize drug interactions, and select
appropriate pharmacologic interventions. This evaluation ensures
successful participants possess the advanced pharmacologic knowledge
necessary for the WGU D116 Objective Assessment.
,SECTION ONE: QUESTIONS 1–100
1. Which of the following best describes the difference between
pharmacokinetics and pharmacodynamics?
A. Pharmacokinetics is what the drug does to the body;
pharmacodynamics is what the body does to the drug
B. Pharmacokinetics is what the body does to the drug;
pharmacodynamics is what the drug does to the body
C. There is no meaningful difference between pharmacokinetics and
pharmacodynamics
D. Pharmacokinetics involves drug efficacy; pharmacodynamics
involves drug metabolism
B. Pharmacokinetics is what the body does to the drug;
pharmacodynamics is what the drug does to the body
RATIONALE: Pharmacokinetics describes "what the body does to
the drug" and encompasses the four processes of absorption,
distribution, metabolism, and excretion (ADME). Pharmacodynamics
describes "what the drug does to the body"—the biochemical and
physiological effects of drugs and their mechanisms of action. This
distinction is fundamental to understanding drug therapy and is a core
concept tested on the WGU D116 OA .
2. A patient with liver cirrhosis is prescribed propranolol. The
APRN understands that the oral bioavailability of this drug will be
significantly increased due to which pharmacokinetic phenomenon?
A. Increased volume of distribution
B. Decreased first-pass metabolism
C. Enhanced renal tubular secretion
D. Increased plasma protein binding
B. Decreased first-pass metabolism
, RATIONALE: Propranolol undergoes extensive first-pass hepatic
metabolism. In cirrhosis, reduced hepatic blood flow and decreased
enzyme activity reduce first-pass extraction, thereby increasing oral
bioavailability. This is a classic example of how hepatic impairment
alters pharmacokinetics .
3. The "first-pass effect" refers to:
A. Rapid intravenous administration of a medication
B. Drug metabolism in the liver before reaching systemic circulation
C. Drug excretion by the kidneys before distribution
D. Drug binding to plasma proteins after absorption
B. Drug metabolism in the liver before reaching systemic circulation
RATIONALE: The first-pass effect occurs when orally administered
drugs are metabolized in the liver before reaching systemic circulation,
reducing bioavailability. Drugs such as nitroglycerin and morphine
require higher oral doses or alternative routes to bypass this effect.
Intravenous administration completely bypasses first-pass metabolism .
4. Bioavailability is defined as:
A. The speed at which a drug is absorbed
B. The fraction of an administered dose that reaches systemic circulation
unchanged
C. The volume of distribution of a drug
D. The half-life of a drug
B. The fraction of an administered dose that reaches systemic
circulation unchanged
, RATIONALE: Bioavailability measures the proportion of an
administered drug dose that reaches the systemic circulation in
unchanged form. Intravenous administration has 100% bioavailability
because it bypasses absorption and first-pass metabolism. Oral
bioavailability is reduced by first-pass metabolism and incomplete
absorption .
5. Which route of administration has the highest bioavailability and
fastest onset of action?
A. Oral
B. Subcutaneous
C. Intravenous (IV)
D. Intramuscular (IM)
C. Intravenous (IV)
RATIONALE: Intravenous administration delivers 100% of the
dose directly into systemic circulation, bypassing absorption barriers and
first-pass metabolism. It provides the most rapid onset of action and is
the preferred route in emergencies requiring immediate drug effect .
6. A drug with a half-life of 4 hours is administered every 4 hours.
Approximately how many half-lives are required to reach steady-
state concentrations?
A. 1
B. 2
C. 4-5
D. 8
C. 4-5
OBJECTIVE ASSESSMENT QUESTIONS AND ANSWERS |
LATEST UPDATE
CORE DOMAINS
• Pharmacokinetics & Pharmacodynamics
• Cardiovascular & Renal Pharmacology
• Respiratory & Allergy Pharmacology
• Endocrine & Metabolic Pharmacology
• Neurologic & Psychiatric Pharmacology
• Infectious Disease & Antimicrobials
• Special Populations, Toxicology & Clinical Application
INTRODUCTION
This comprehensive assessment evaluates the candidate's mastery of
advanced pharmacology principles required for safe, evidence-based
prescribing at the APRN level. It measures competency across
pharmacokinetics, pharmacodynamics, drug classifications, adverse
effects, drug interactions, and therapeutic monitoring. The examination
employs multiple-choice and scenario-based questions that test clinical
reasoning, prioritization, and application of pharmacologic principles to
complex patient scenarios. Candidates must demonstrate the ability to
evaluate drug therapy, recognize drug interactions, and select
appropriate pharmacologic interventions. This evaluation ensures
successful participants possess the advanced pharmacologic knowledge
necessary for the WGU D116 Objective Assessment.
,SECTION ONE: QUESTIONS 1–100
1. Which of the following best describes the difference between
pharmacokinetics and pharmacodynamics?
A. Pharmacokinetics is what the drug does to the body;
pharmacodynamics is what the body does to the drug
B. Pharmacokinetics is what the body does to the drug;
pharmacodynamics is what the drug does to the body
C. There is no meaningful difference between pharmacokinetics and
pharmacodynamics
D. Pharmacokinetics involves drug efficacy; pharmacodynamics
involves drug metabolism
B. Pharmacokinetics is what the body does to the drug;
pharmacodynamics is what the drug does to the body
RATIONALE: Pharmacokinetics describes "what the body does to
the drug" and encompasses the four processes of absorption,
distribution, metabolism, and excretion (ADME). Pharmacodynamics
describes "what the drug does to the body"—the biochemical and
physiological effects of drugs and their mechanisms of action. This
distinction is fundamental to understanding drug therapy and is a core
concept tested on the WGU D116 OA .
2. A patient with liver cirrhosis is prescribed propranolol. The
APRN understands that the oral bioavailability of this drug will be
significantly increased due to which pharmacokinetic phenomenon?
A. Increased volume of distribution
B. Decreased first-pass metabolism
C. Enhanced renal tubular secretion
D. Increased plasma protein binding
B. Decreased first-pass metabolism
, RATIONALE: Propranolol undergoes extensive first-pass hepatic
metabolism. In cirrhosis, reduced hepatic blood flow and decreased
enzyme activity reduce first-pass extraction, thereby increasing oral
bioavailability. This is a classic example of how hepatic impairment
alters pharmacokinetics .
3. The "first-pass effect" refers to:
A. Rapid intravenous administration of a medication
B. Drug metabolism in the liver before reaching systemic circulation
C. Drug excretion by the kidneys before distribution
D. Drug binding to plasma proteins after absorption
B. Drug metabolism in the liver before reaching systemic circulation
RATIONALE: The first-pass effect occurs when orally administered
drugs are metabolized in the liver before reaching systemic circulation,
reducing bioavailability. Drugs such as nitroglycerin and morphine
require higher oral doses or alternative routes to bypass this effect.
Intravenous administration completely bypasses first-pass metabolism .
4. Bioavailability is defined as:
A. The speed at which a drug is absorbed
B. The fraction of an administered dose that reaches systemic circulation
unchanged
C. The volume of distribution of a drug
D. The half-life of a drug
B. The fraction of an administered dose that reaches systemic
circulation unchanged
, RATIONALE: Bioavailability measures the proportion of an
administered drug dose that reaches the systemic circulation in
unchanged form. Intravenous administration has 100% bioavailability
because it bypasses absorption and first-pass metabolism. Oral
bioavailability is reduced by first-pass metabolism and incomplete
absorption .
5. Which route of administration has the highest bioavailability and
fastest onset of action?
A. Oral
B. Subcutaneous
C. Intravenous (IV)
D. Intramuscular (IM)
C. Intravenous (IV)
RATIONALE: Intravenous administration delivers 100% of the
dose directly into systemic circulation, bypassing absorption barriers and
first-pass metabolism. It provides the most rapid onset of action and is
the preferred route in emergencies requiring immediate drug effect .
6. A drug with a half-life of 4 hours is administered every 4 hours.
Approximately how many half-lives are required to reach steady-
state concentrations?
A. 1
B. 2
C. 4-5
D. 8
C. 4-5
